10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Slightly more than a month after the US Food and Drug Administration approved the product, the European Commission (EC) has also granted marketing authorization for Darzalex (daratumumab) subcutaneous (SC) formulation for the treatment of adult patients with multiple myeloma (MM), says US healthcare giant Johnson & Johnson. 5 June 2020
Privately-held German firm Immatics Biotechnologies today announced that Cedrik Britten has been appointed as chief medical officer (CMO) effective June 1, 2020. 4 June 2020
South Korean LegoChem Biosciences has entered a worldwide license agreement with Newcastle, UK-based Iksuda Therapeutics for the development and commercialization of LCB73, a CD19-targeted ADC candidate for hematological tumors. 4 June 2020
Canada-based biotech FSD Pharma saw its shares skyrocket 127% to C$9.65 by close of trading Wednesday, after it revealed that the US Food and Drug Administration had given the company permission to submit an Investigational New Drug Application (IND) for the use of its lead candidate FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus. 4 June 2020
The European Commission (EC) has approved Braftovi (encorafenib) in combination with cetuximab for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy, says privately-held French drugmaker Pierre Fabre. 4 June 2020
Pharma giant Novartis has announced full positive results from the Phase III PREVENT trial of Cosentyx (secukinumab) in axial spondyloarthritis. 4 June 2020
Life sciences venture capital firm Forbion says that its newest portfolio company, Prilenia Therapeutics, a Naarden, Netherlands- and Herzliya, Israel-based clinical stage biotech company, has raised $62.5 million in a Series A financing round. 4 June 2020
Of around 50 biopharma companies and contract manufacturing organizations that took advantage of a US government $659 billion loan program, five are working on COVID-19 therapies. 3 June 2020
Interleukin (IL)-17A antagonist Taltz (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data to be presented virtually on June 5 at the European Congress of Rheumatology 2020 (EULAR). 3 June 2020
US pharma major Bristol-Myers Squibb today announced results from the open-label switch period of Early AMPLE, a Phase IV exploratory biomarker study assessing the differences by which Orencia (abatacept) and another treatment, adalimumab, interfere with disease progression in moderate-to-severe early rheumatoid arthritis (RA) patients who tested positive (seropositive) for certain autoantibodies. 3 June 2020
China-based biotech BeiGene today revealed that its BTK inhibitor Brukinsa(zanubrutinib) has received approval from the China National Medical Products Administration (NMPA) in two indications. 3 June 2020
US biotech Regeneron Pharmaceuticals has failed to invalidate a fifth Kymab patent, covering genetically-modified mice used to produce human antibody therapeutics. 3 June 2020
Novo Ventures, part of Denmark’s Novo Holdings, today announced that it has led the $55 million Series B financing in UK and USA-based biotech NodThera, which is developing a new class of medicines to treat diseases driven by chronic inflammation. Nanna Lüneborg, a partner at Novo Ventures, will join the NodThera board. 3 June 2020
Swiss biotech Relief Therapeutics and its US partner, NeuroRx, have announced the start of treatment of patients with RLF-100 at the University of Miami Miller School of Medicine. 3 June 2020
Pfizer, at a time when the COVID-19 pandemic is disrupting drugmakers clinical trials activities, on Tuesday announced the establishment of the Pfizer Breakthrough Growth Initiative, through which the US pharma giant will invest up to $500 million in biotechnology companies to help provide funding and access to Pfizer’s scientific expertise to ensure continuity of the biotechnology companies’ most promising clinical development programs. 3 June 2020
Danish dermatology specialist LEO Pharma has promised a plethora of data from Phase III trials in atopic dermatitis (AD) and psoriasis at this year’s American Academy of Dermatology (AAD) virtual meeting later this month. 2 June 2020
The European Commission (EC) has approved Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. 2 June 2020
The US Department of Health and Human Services (HHS) has added $628 million to its contract with Emergent BioSolutions to advance manufacturing capabilities and capacity for a potential COVID-19 vaccine as well as therapeutics. 2 June 2020